Aktuellt
SENASTE
Idefirix accounts a relatively solid Q3 despite holiday interruptions. This is combined with collaboration genetic progress which converts earlier cash considerations into Q3 sales support. We expect a positive reaction compared with the regional equity market but be aware of the non-recurring nature of collaboration related sales support.
LÄS MER
